In the last trading session, 0.15 million shares of the Hepion Pharmaceuticals Inc (NASDAQ:HEPA) were traded, and its beta was 1.71. Most recently the company’s share price was $0.47, and it changed around $0.04 or 9.25% from the last close, which brings the market valuation of the company to $3.27M. HEPA currently trades at a discount to its 52-week high of $3.49, offering almost -642.55% off that amount. The share price’s 52-week low was $0.43, which indicates that the current value has risen by an impressive 8.51% since then. We note from Hepion Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 33190.0 shares, with the 3-month average coming to 45.59K.
Hepion Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 3.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended HEPA as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Hepion Pharmaceuticals Inc is expected to report earnings per share of 0 for the current quarter.
Hepion Pharmaceuticals Inc (NASDAQ:HEPA) trade information
Instantly HEPA has showed a green trend with a performance of 9.25% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.5144 on recent trading dayincreased the stock’s daily price by 8.63%. The company’s shares are currently down -85.49% year-to-date, but still down -5.96% over the last five days. On the other hand, Hepion Pharmaceuticals Inc (NASDAQ:HEPA) is -29.63% down in the 30-day period. We can see from the shorts that 65726.0 shares have been sold at a short interest cover period of 0.92 day(s).
The consensus price target as assigned by Wall Street analysts is $70, which translates to bulls needing to increase their stock price by 99.33% from its current value. Analyst projections state that HEPA is forecast to be at a low of $70 and a high of $70.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 63.67%.
HEPA Dividends
Hepion Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in February.
Hepion Pharmaceuticals Inc (NASDAQ:HEPA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.08% of Hepion Pharmaceuticals Inc shares, and 7.85% of them are in the hands of institutional investors. The stock currently has a share float of 7.85%.
